



**Report Number:** 22-001043/D006.R000

**Report Date:** 02/03/2022 **ORELAP#:** OR100028

**Purchase Order:** 

**Received:** 01/27/22 16:45


Customer: IHC LLC

Product identity: 0107LIRVAP200\_OGK

Client/Metrc ID:

**Laboratory ID:** 22-001043-0008

## Summary







IHC LLC **Customer:** 

> 825 NW 16th Ave Portland Oregon 97209

United States of America (USA)

Product identity: 0107LIRVAP200\_OGK

Client/Metrc ID:

Sample Date:

Laboratory ID: 22-001043-0008

**Evidence of Cooling:** Temp: 17.5 °C Relinquished by: Client

**Report Number:** 22-001043/D006.R000

02/03/2022 Report Date: ORELAP#: OR100028

**Purchase Order:** 

Received: 01/27/22 16:45



# **Sample Results**

| Potency                 | Method J | AOAC 2 | 2015 V98 | -6 (mod) | Units % | Batch: 2200974 | <b>Analyze:</b> 2/3/22 | 12:16:00 AM                       |
|-------------------------|----------|--------|----------|----------|---------|----------------|------------------------|-----------------------------------|
| Analyte                 | As       | Dry    | LOQ      | Notes    |         |                |                        |                                   |
|                         | Received | weight |          |          |         |                |                        | <ul><li>CBD</li></ul>             |
| CBC                     | 6.45     |        | 0.0978   |          |         |                |                        | • CBN                             |
| CBC-A <sup>†</sup>      | 0.491    |        | 0.0978   |          |         |                |                        | • CBC                             |
| CBC-Total <sup>†</sup>  | 6.88     |        | 0.184    |          |         |                |                        | <ul><li>CBT</li><li>CBE</li></ul> |
| CBD                     | 33.6     |        | 0.978    |          |         |                |                        | O CBD-A                           |
| CBD-A                   | 3.66     |        | 0.0978   |          |         |                |                        | • CBG                             |
| CBD-Total               | 36.8     |        | 1.06     |          |         |                |                        | <ul><li>CBC-A</li></ul>           |
| CBDV <sup>†</sup>       | 0.476    |        | 0.0978   |          |         |                |                        | <ul><li>CBDV</li></ul>            |
| CBDV-A <sup>†</sup>     | < LOQ    |        | 0.0978   |          |         |                |                        | <ul><li>THC-A</li></ul>           |
| CBDV-Total <sup>†</sup> | 0.476    |        | 0.183    |          |         |                |                        |                                   |
| CBE <sup>†</sup>        | 3.86     |        | 0.0978   |          |         |                |                        |                                   |
| CBG <sup>†</sup>        | 3.18     |        | 0.0978   |          |         |                |                        |                                   |
| CBG-A <sup>†</sup>      | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| CBG-Total               | 3.18     |        | 0.183    |          |         |                |                        |                                   |
| CBL <sup>†</sup>        | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| CBL-A <sup>†</sup>      | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| CBL-Total <sup>†</sup>  | < LOQ    |        | 0.184    |          |         |                |                        |                                   |
| CBN                     | 18.1     |        | 0.0978   |          |         |                |                        |                                   |
| CBT <sup>†</sup>        | 5.23     |        | 0.0978   |          |         |                |                        |                                   |
| Δ8-THC <sup>†</sup>     | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| Δ8-THCV                 | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| Δ9-THC                  | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| THC-A                   | 0.131    |        | 0.0978   |          |         |                |                        |                                   |
| THC-Total               | < LOQ    |        | 0.184    |          |         |                |                        |                                   |
| THCV <sup>†</sup>       | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| THCV-A <sup>†</sup>     | < LOQ    |        | 0.0978   |          |         |                |                        |                                   |
| THCV-Total <sup>†</sup> | < LOQ    |        | 0.183    |          |         |                |                        |                                   |
| Total Cannabinoids†     | 75.2     |        |          |          |         |                |                        |                                   |





Report Number: 22-001043/D006.R000

**Report Date:** 02/03/2022 **ORELAP#:** OR100028

**Purchase Order:** 

**Received:** 01/27/22 16:45

These test results are representative of the individual sample selected and submitted by the client.

#### **Abbreviations**

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

**Limit(s) of Quantitation (LOQ):** The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

† = Analyte not NELAP accredited.

#### Units of Measure

% = Percentage of sample % wt =  $\mu$ g/g divided by 10,000

Approved Signatory

Derrick Tanner General Manager





**Report Number:** 22-001043/D006.R000

**Report Date:** 02/03/2022 ORELAP#: OR100028

**Purchase Order:** 

01/27/22 16:45 Received:



## Hemp / Cannabis Usable / Extract / Finished Products Chain of Custody Record

Revision: 4.00 Control#: CF023 Rev 02/24/2021 Eff: 03/04/2021 ORELAP ID: OR100028

|  |      |                   |  |           |         | A                 | nalys    | is Req                | ueste              | d          |              |            |  | D.C             | Number:           |                   |
|--|------|-------------------|--|-----------|---------|-------------------|----------|-----------------------|--------------------|------------|--------------|------------|--|-----------------|-------------------|-------------------|
| Company: IHC Contact: Kyle Farook Street: 431 NW Flanders st. City: Portland State: OF Zip: 97209  Email Results: dropbox  Ph: (61) 608164 Fx Results: Billing (if different): beth@thehempcollect.cor |      | - OR 59 compounds | esticide Multi-Residue – 379 compounds |           |         | r Activity .      |          | Micro: Yeast and Mold | and Total Coliform | ls .       |              |            | PO Number:  Project Number:  Project Name:  Custom Reporting:  Report to State - |                 |                   |                   |
| Lab  ID Client Sample Identification   | Date | Time              | Pesticides -                           | Pesticide | Potency | Residual Solvents | Moisture | Terpenes              | Micro: Ye          | Micro: E.0 | Heavy Metals | Mycotoxins | Other:   | Sample<br>Type† | Weight<br>(Units) | Comments/Metrc ID |
| 1 0103LIRVAP200_ST   | 1/27 |                   |  |           | X       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 2 0103LIRVAP200_SG   | 1/27 |                   |  |           | Х       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 3 0103LIRVAP200_OG   | 1/27 |                   |  |           | Х       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 4 0103LIRVAP200_SP   | 1/27 |                   |  |           | Х       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 5 0103LIRVAP200_PB   | 1/27 |                   |  |           | Х       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 6 01020506LIRVAP_PW  | 1/27 | 1                 | $\vdash$                               |           | Х       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 7 01020506LIRVAP_FV  | 1/27 | 1                 | +                                      |           | Х       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 8 0107LIRVAP200_OGK  | 1/27 |                   | 1                                      |           | Х       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
| 9 01020506LIRBRD_FV  |      | -                 | 1                                      | _         | X       |                   |          |                       |                    |            |              |            |  | E               |                   |                   |
|  | 1/27 | -                 | +                                      |           | Х       |                   |          | Х                     |                    |            |              |            | _  | V               |                   |                   |
| Relinguished By:   | Date | Time              |  |           | Re      | eceived           | Bv:      |                       |                    | Da         | te           | Tir        | me   |                 |                   | Lab Use Only:     |
| Kyle Farook 1/27 4:45 DS 1/21/22 16-45 Evidence of cooling: DYS Sample in good conditions  |      |                   | Yes → No - Temp (°C):                  |           |         |                   |          |                       |                    |            |              |            |  |                 |                   |                   |

†-Sample Type Codes: Vegetation (V); Isolates (S); Extract/Concentrate (C); Tincture/Topical (T); Edible (E); Beverage (B)

Samples submitted to Columbia Laboratories with testing requirements constitute an agreement for services in accordance with the current terms of service associated with this COC. By signing "Relinquished by" you are agreeing to these terms 12423 NE Whitaker Way P: (503) 254-1794 | Fax: (503) 254-1452 Page \_\_\_\_of\_ www.columbialaboratories.com Portland, OR 97230





**Report Number:** 22-001043/D006.R000

02/03/2022 Report Date: ORELAP#: OR100028

**Purchase Order:** 

Received: 01/27/22 16:45

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

#### **Laboratory Quality Control Results**

| J AOAC 2015 V9  |             |       |       |       |            |            |       |
|-----------------|-------------|-------|-------|-------|------------|------------|-------|
| Laboratory Conf | trol Sample |       |       |       |            |            |       |
| Analyte         | Result      | Spike | Units | % Rec | Limits     | Evaluation | Notes |
| CBDVA           | 0.192       | 0.2   | %     | 95.9  | 85.0 - 115 | Acceptable |       |
| CBDV            | 0.201       | 0.2   | %     | 100   | 85.0 - 115 | Acceptable |       |
| CBE             | 0.196       | 0.2   | %     | 98.2  | 85.0 - 115 | Acceptable |       |
| CBDA            | 0.213       | 0.2   | %     | 107   | 85.0 - 115 | Acceptable |       |
| CBGA            | 0.192       | 0.2   | %     | 95.8  | 85.0 - 115 | Acceptable |       |
| CBG             | 0.188       | 0.2   | %     | 94.2  | 85.0 - 115 | Acceptable |       |
| CBD             | 0.206       | 0.2   | %     | 103   | 85.0 - 115 | Acceptable |       |
| THCV            | 0.185       | 0.2   | %     | 92.5  | 85.0 - 115 | Acceptable |       |
| d8THCV          | 0.188       | 0.2   | %     | 93.8  | 85.0 - 115 | Acceptable |       |
| THCVA           | 0.189       | 0.2   | %     | 94.4  | 85.0 - 115 | Acceptable |       |
| CBN             | 0.207       | 0.2   | %     | 103   | 85.0 - 115 | Acceptable |       |
| exo-THC         | 0.176       | 0.2   | %     | 88.2  | 85.0 - 115 | Acceptable |       |
| d9THC           | 0.196       | 0.2   | %     | 98.0  | 85.0 - 115 | Acceptable |       |
| d8THC           | 0.171       | 0.2   | %     | 85.6  | 85.0 - 115 | Acceptable |       |
| CBL             | 0.184       | 0.2   | %     | 91.8  | 85.0 - 115 | Acceptable |       |
| CBC             | 0.182       | 0.2   | %     | 91.1  | 85.0 - 115 | Acceptable |       |
| THCA            | 0.204       | 0.2   | %     | 102   | 85.0 - 115 | Acceptable |       |
| CBCA            | 0.196       | 0.2   | %     | 97.9  | 85.0 - 115 | Acceptable |       |
| CBLA            | 0.198       | 0.2   | %     | 98.9  | 85.0 - 115 | Acceptable |       |
| CBT             | 0.226       | 0.2   | %     | 113   | 85.0 - 115 | Acceptable |       |

#### **Method Blank**

| Analyte | Result   | LOQ | Units | Limits | Evaluation | Notes |
|---------|--|-----|-------|--------|------------|-------|
| CBDVA   | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBDV    | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBE     | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBDA    | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBGA    | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBG     | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBD     | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| THCV    | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| d8THCV  | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| THCVA   | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBN     | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| exo-THC | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| d9THC   | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| d8THC   | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBL     | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBC     | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| THCA    | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBCA    | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBLA    | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |
| CBT     | <loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | %     | < 0.1  | Acceptable |       |

## **Abbreviations**

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

## Units of Measure:

% - Percent





**Report Number:** 22-001043/D006.R000

02/03/2022 Report Date: ORELAP#: OR100028

**Purchase Order:** 

Received: 01/27/22 16:45

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

### **Laboratory Quality Control Results**

| J AOAC 2015 V98-6 Batch ID: 2200974 |  |  |                                  |       |       |        |            |       |  |  |  |
|-------------------------------------|--|--|----------------------------------|-------|-------|--------|------------|-------|--|--|--|
| Sample Duplic                       | ate  |  | Sample ID: <b>22-001043-0001</b> |       |       |        |            |       |  |  |  |
| Analyte                             | Result   | Org. Result  | LOQ                              | Units | RPD   | Limits | Evaluation | Notes |  |  |  |
| CBDVA                               | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| CBDV                                | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| CBE                                 | 0.241  | 0.230  | 0.1                              | %     | 4.81  | < 20   | Acceptable |       |  |  |  |
| CBDA                                | 2.30   | 2.28   | 0.1                              | %     | 0.721 | < 20   | Acceptable |       |  |  |  |
| CBGA                                | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| CBG                                 | 0.232  | 0.215  | 0.1                              | %     | 7.55  | < 20   | Acceptable |       |  |  |  |
| CBD                                 | 2.58   | 2.52   | 0.1                              | %     | 2.20  | < 20   | Acceptable |       |  |  |  |
| THCV                                | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| d8THCV                              | 0.455  | 0.427  | 0.1                              | %     | 6.43  | < 20   | Acceptable |       |  |  |  |
| THCVA                               | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| CBN                                 | 0.403  | 0.373  | 0.1                              | %     | 7.70  | < 20   | Acceptable |       |  |  |  |
| exo-THC                             | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| d9THC                               | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| d8THC                               | 78.1   | 77.7   | 0.1                              | %     | 0.462 | < 20   | Acceptable |       |  |  |  |
| CBL                                 | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| CBC                                 | 0.485  | 0.477  | 0.1                              | %     | 1.63  | < 20   | Acceptable |       |  |  |  |
| THCA                                | 0.255  | 0.245  | 0.1                              | %     | 3.76  | < 20   | Acceptable |       |  |  |  |
| CBCA                                | 0.249  | 0.246  | 0.1                              | %     | 0.919 | < 20   | Acceptable |       |  |  |  |
| CBLA                                | <loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<> | 0.1                              | %     | NA    | < 20   | Acceptable |       |  |  |  |
| CBT                                 | 0.586  | 0.521  | 0.1                              | %     | 11.7  | < 20   | Acceptable |       |  |  |  |

#### **Abbreviations**

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

### Units of Measure:

% - Percent





**Report Number:** 22-001043/D006.R000

Report Date: 02/03/2022 ORELAP#: OR100028

**Purchase Order:** 

Received: 01/27/22 16:45

## Explanation of QC Flag Comments:

| Code | Explanation   |
|------|---|
| Q    | Matrix interferences affecting spike or surrogate recoveries.                               |
| Q1   | Quality control result biased high. Only non-detect samples reported.                       |
| Q2   | Quality control outside QC limits. Data considered estimate.                                |
| Q3   | Sample concentration greater than four times the amount spiked.                             |
| Q4   | Non-homogenous sample matrix, affecting RPD result and/or % recoveries.                     |
| Q5   | Spike results above calibration curve.  |
| Q6   | Quality control outside QC limits. Data acceptable based on remaining QC.                   |
| R    | Relative percent difference (RPD) outside control limit.                                    |
| R1   | RPD non-calculable, as sample or duplicate results are less than five times the LOQ.        |
| R2   | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution.                         |
| LOQ2 | Quantitaion level raised due to matrix interference.  |
| В    | Analyte detected in method blank, but not in associated samples.                            |
| B1   | The sample concentration is greater than 5 times the blank concentration.                   |
| B2   | The sample concentration is less than 5 times the blank concentration.                      |